Halozyme Therapeutics (HALO) Tops Q2 EPS by 26c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Halozyme Therapeutics (HALO) PT Raised to $66 at BMO Capital
August 10, 2021 9:04 AM EDTBMO Capital analyst Do Kim raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $66.00 (from $64.00) while maintaining an Outperform rating.
The analyst commented, "HALO reported 2Q21 royalty revenues of $45.8mn, ahead of our $40.9mn estimate and consensus' $45.4mn. 2021 guidance was also revised... More
